Paul Majkowski authored, “Is an East Coast Version of Prop 65 in Our Future,” for the November 2019 issue of IADC – Toxic and Hazardous Substance Litigation Newsletter. Click here to read. …
Read More

Paul Majkowski published an article in the American Bar Association’s Mass Torts Litigation section, “Boyle to Burn Pits and Beyond: A Government Contractor Defense Refresher.” Click here to read the article. …
Read More

Paul Majkowski authored an article in the American Bar Association’s Mass Torts Litigation Practice Points section, “Prop 65 Heads East?” Click here to read the article. …
Read More

Paul Majkowski wrote an article published in the American Bar Association Mass Torts Litigation Practice Points section, “PFAS Class Seeks Court Ordered “Independent Panel of Scientists.” Click here to read the article. …
Read More

Paul Majkowski published an article entitled, “Update on Glyphosate: The Roundup MDL General Causation Daubert Hearings,” in Mass Torts Litigation, a publication of the American Bar Association’s Section of Litigation. The article discusses Judge Vince Chhabria’s comments in a Daubert hearing conducted on general causation as to non-Hodgkin’s lymphoma, which heard from a dozen witnesses. To read …
Read More

Brian Feld’s article, “Mutation and Evolution: The Effect of the BAP1 Gene on Asbestos Litigation,” appeared in the December 29, 2017, newsletter of DRI’s Toxic Tort and Environmental Law Committee. To read the article, click here. …
Read More

Paul Majkowski published an article in the American Bar Association – Mass Torts Litigation, “Update to In re: General Mills Glyposate Litigation. Click here to read. …
Read More

Data often is the lifeblood of a business. When a database is breached in one way or another, the results can be devastating—especially if the data falls into the hands of a competitor. Many companies suffering this kind of loss turn to litigation. Perhaps in an effort to obtain federal court jurisdiction, they may assert …
Read More

As is frequently the case, a regulatory development or finding will serve as the impetus for activity in the realm of toxic tort. From the plaintiff’s perspective, the underlying science has been given the patina of credibility by the regulatory action; from the defense view, the regulatory action does not elevate the underlying science to …
Read More

There is a potential compliance “blind spot” associated with what many in the healthcare industry would regard as ordinary practice acquisitions and joint ventures involving hospitals and other provider organizations. This area of possible vulnerability arises from the payment of consideration for what are sometimes insufficiently delineated assets of the target or partner entity. If …
Read More